Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.
Chinmedomics facilitated quality-marker discovery of Sijunzi decoction to treat spleen qi deficiency syndrome
Qiqi Zhao1, Xin Gao1, Guangli Yan1, Aihua Zhang1, Hui Sun1, Ying Han1, Wenxiu Li1, Liang Liu2, Xijun Wang1,2,3()
1. National Chinmedomics Research Center, Sino-America Chinmedomics Technology Collaboration Center, National TCM Key Laboratory of Serum Pharmacochemistry, Laboratory of Metabolomics, Department of Pharmaceutical Analysis, Heilongjiang University of Chinese Medicine, Harbin 150040, China
2. State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China
3. National Engineering Laboratory for the Development of Southwestern Endangered Medicinal Materials, Guangxi Botanical Garden of Medicinal Plant, Nanning 530023, China
 Download: PDF(5317 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Sijunzi decoction (SJZD) is a Chinese classical formula to treat spleen qi deficiency syndrome (SQDS) and has been widely used for thousands of years. However, the quality control (QC) standards of SJZD are insufficient. Chinmedomics has been designed to discover and verify bioactive compounds of a variety of formula rapidly. In this study, we used Chinmedomics to evaluate the SJZD’s efficacy against SQDS to discover the potential quality-markers (q-markers) for QC. A total of 56 compounds in SJZD were characterized in vitro, and 23 compounds were discovered in vivo. A total of 58 biomarkers were related to SQDS, and SJZD can adjust a large proportion of marker metabolites to normal level and then regulate the metabolic profile to the health status. A total of 10 constituents were absorbed as effective ingredients that were associated with overall efficacy. We preliminarily determined malonyl-ginsenoside Rb2 and ginsenoside Ro as the q-markers of ginseng; dehydrotumulosic acid and dihydroxy lanostene-triene-21-acid as the q-markers of poria; glycyrrhizic acid, isoglabrolide, and glycyrrhetnic acid as the q-markers of licorice; and 2-atractylenolide as the q-marker of macrocephala. According to the discovery of the SJZD q-markers, we can establish the quality standard that is related to efficacy.

Keywords traditional Chinese medicine      Sijunzi decoction      spleen qi deficiency syndrome      Chinmedomics      quality-marker     
Corresponding Authors: Xijun Wang   
Just Accepted Date: 08 August 2019   Online First Date: 26 November 2019   
 Cite this article:   
Qiqi Zhao,Xin Gao,Guangli Yan, et al. Chinmedomics facilitated quality-marker discovery of Sijunzi decoction to treat spleen qi deficiency syndrome[J]. Front. Med., 26 November 2019. [Epub ahead of print] doi: 10.1007/s11684-019-0705-9.
Fig.1  Model evaluation of spleen qi deficiency syndrome. (A) Body weight between the CON and MOD groups. (B) Spleen and thymus indices between the CON and MOD groups. (C) General state of model rats during model replication period. (D) Gastric food remnant and small intestine propulsive rates between the CON and MOD groups. (E) Gastric and small intestinal mucosa from the MOD group showed disorderly epithelial cells, unclearly muscular layer, slight erosion and exudation. (F) Serum D-xylose level and amylase level between CON and MOD groups. (G) GAS and MOT level between CON and MOD groups. *P<0.05 and **P<0.01 compared with the CON group.
Fig.2  SJZD efficacy evaluation on spleen qi deficiency syndrome. (A) Body weight of the control, model, and SJZD groups. (B) Spleen and thymus indices of the control, model, and SJZD groups. (C) Gastric food remnant and small intestine propulsive rates of the control, model, and SJZD groups. (D) GAS and MOT level of the control, model, and SJZD groups. (E) Gastric and small intestinal mucosa from the SJZD group showed improved epithelial cells and tissue lesion. (F) Serum D-xylose level, amylase level, GAS, and MOT level of the control, model, and SJZD groups. *P<0.05 and **P<0.01 compared with the control group; #P<0.05 and ##P<0.01 compared with the model group.
Fig.3  Multivariate analysis in SQDS serum and urine metabolomics study. (A) PCA score plot (above) and OPLS-DA score plot (below) between different groups in serum metabolomics study. (B) Time trajectory of rat urine during the model replication. (C) PCA score plot (left) and OPLS-DA score plot (right) between different groups in urine metabolomics study.
Fig.4  Chemical structure and the mass fragment information of indole-3-carboxylic acid, identified as the SQDS rat urine biomarker in positive ion mode. The precise molecular mass and the fragments were detected by a mass spectrometer (UPLC-Q-TOF-MS) and determined within a reasonable degree of measurement error (<5 mDa).
No. Rt M/Z determined M/Z calculated Adducts Actual_M Proposed composition Postulated identity Trend
1 1.08 136 136 M+ Na 113.05 C5H7NO2 1-Pyrroline-2-carboxylic acid
2 1.09 154 154.1 M+ H 153.04 C7H7NO3 3-Hydroxyanthranilic acid
3 1.68 157.1 157.1 M+ Na 134.07 C4H10N2O3 L-Canaline
4 2.19 201 201 M − H 202.03 C11H6O4 Bergaptol
5 2.54 514.3 514.3 M − H 515.29 C26H45NO7S Taurocholic acid
6 2.81 448.3 448.3 M − H 449.31 C26H43NO5 Chenodeoxyglycocholic acid
7 3.6 315.2 315.2 M − H 316.2 C20H28O3 4-Hydroxyretinoic acid
8 3.64 282.3 282.3 M+ H 281.27 C18H35NO Oleamide
9 3.91 333.2 333.2 M − H 334.21 C20H30O4 Prostaglandin A2
10 3.91 289.2 289.2 M+ H 288.21 C19H28O2 Testosterone
11 3.93 518.3 518.3 M+ H 517.32 C26H48NO7P LysoPC(18:3(9Z,12Z,15Z))
12 4.31 303.2 303.2 M − H 304.24 C20H32O2 Arachidonic acid
13 4.84 255.2 255.2 M − H 256.24 C16H32O2 Palmitic acid
14 4.9 1092 1092 M+ H 1090.7 C56H102N2O18 Ganglioside GA2 (d18:1/9Z-18:1)
15 5.01 295.2 295.2 M − H 296.24 C18H32O3 9,10-Epoxyoctadecenoic acid
16 6.19 552.4 552.4 M+ H 551.4 C28H58NO7P LysoPC(20:0)
17 6.73 780.6 780.6 M+ Na 757.56 C42H80NO8P PC(18:1(11Z)/16:1(9Z))
18 7.02 253.2 253.2 M − H 254.22 C16H30O2 Palmitoleic acid
19 7.13 742.5 742.5 M − H 743.55 C41H78NO8P PC(15:0/18:2(9Z,12Z))
20 7.28 578.4 578.4 M+ H 577.41 C30H60NO7P LysoPC(22:1(13Z))
21 7.42 808.6 808.6 M+ H 807.58 C46H82NO8P PC(20:2(11Z,14Z))
Tab.1  Detailed information of biomarkers tentatively identified by serum metabolomics
No. Rt M/Z
Adducts_H+ Adducts_H− Actual_M Proposed ?composition Postulated identity Trend
1 0.68 195.0504 195.0505 195.051 196.0583 C6H12O7 Galactonic acid
2 0.71 114.0661 114.0672 114.067 113.0589 C4H7N3O Creatinine
3 0.76 300.0389 300.0389 300.039 301.0468 C8H15NO9S N-Acetylglucosamine 6-sulfate
4 0.77 203.1508 203.1511 203.15 202.143 C8H18N4O2 Dimethyl-L-arginine
5 0.79 335.0955 339.0961 335.096 334.0907 C17H19ClN2OS Chlorpromazine-N-oxide
6 0.8 243.0973 243.0971 243.098 242.0903 C10H14N2O5 Thymidine
7 0.84 149.0451 149.0445 149.044 150.0528 C5H10O5 β-D-ribopyranose
8 0.89 70.0651 70.0655 70.0654 69.0578 C4H7N 1-Pyrroline
9 0.89 132.0665 132.067 132.066 131.0582 C5H9NO3 4-Hydroxy-L-proline
10 0.9 191.0186 191.0191 191.019 192.027 C6H8O7 Citric acid
11 0.9 173.0079 173.0083 173.008 174.0164 C6H6O6 Trans-aconitic acid
12 1.21 121.065 121.0653 121.065 120.0575 C8H8O Phenylacetaldehyde
13 1.21 138.0915 138.0911 138.092 137.0841 C8H11NO Tyramine
14 1.29 111.0086 111.0081 111.008 112.016 C5H4O3 2-Furoic acid
15 1.29 173.0075 173.0081 173.008 174.0164 C6H6O6 Dehydroascorbic acid
16 1.69 238.0935 238.0929 238.094 237.0862 C9H11N5O3 Dyspropterin
17 1.95 136.0753
136.076 134.06 135.0684 C8H9NO N-Acetylarylamine
18 2.5 208.0969 208.0971 208.097 207.0895 C11H13NO3 N-Acetyl-L-phenylalanine
19 2.74 220.1183 220.118 220.118 219.112 C10H13N5O Cis-zeatin
20 2.85 279.1335 279.1336 279.134 278.1267 C14H18N2O4 N1-(α-D-ribosyl)-5, 6-?dimethyl-benzimidazole
21 2.94 216.9804 216.981 216.981 217.9885 C7H6O6S 5-Sulfosalicylic acid
22 3.02 162.0561
162.055 160.039 161.0477 C9H7NO2 Indole-3-carboxylic acid
23 3.23 167.0335 167.0338 167.034 168.0423 C8H8O4 Homogentisic acid
24 3.41 206.0448
206.045 204.029 205.0375 C10H7NO4 Xanthurenic acid
25 3.74 190.0449 190.0512 190.05 189.0426 C10H7NO3 Kynurenic acid
26 3.95 208.0607 208.0612 208.061 207.0532 C10H9NO4 4-(2-Aminophenyl)-2, 4-?dioxobutanoic acid
27 4.27 178.0492 178.0495 178.05 179.0582 C9H9NO3 Hippuric acid
28 4.57 164.0722
164.071 162.055 163.0633 C9H9NO2 3-Methyldioxyindole
29 4.57 340.1041
340.104 338.088 339.0954 C15H17NO8 6-Hydroxy-5-methoxyindole ?glucuronide
30 4.8 192.0658 192.0661 192.066 193.0739 C10H11NO3 Phenylacetylglycine
31 5.18 229.143 229.1433 229.143 230.1518 C12H22O4 Dodecanedioic acid
32 5.37 173.0813 173.0809 173.081 174.0892 C8H14O4 Suberic acid
33 6.15 255.0671
255.066 253.05 254.0573 C7H14N2O6S 5-L-Glutamyl-taurine
34 6.23 297.0975 297.0983 297.098 298.1053 C14H18O7 2-Phenylethanol glucuronide
35 6.23 175.0241 175.0235 175.024 176.0321 C6H8O6 D-Glucurono-6,3-lactone
36 7.2 181.0862 181.086 181.086 180.0786 C10H12O3 Coniferyl alcohol
37 8.48 407.2785 407.2793 407.279 408.2876 C24H40O5 Cholic acid
Tab.2  Detailed information of biomarkers tentatively identified by urine metabolomics
Fig.5  Serum and urine biomarker relative measurements before and after SJZD treatment. (A) 37 urine metabolites. (B) 21 serum metabolites. (*P<0.05 and **P<0.01 compared with the control group; #P<0.05 and ##P<0.01 compared with the model group.)
Fig.6  Metabolite profile after orally administrated SJZD and the urine/serum metabolites relative-disordered pathway. (A) Urine metabolite profile. (B) Urine metabolite profile. (C) Urine metabolite relative pathways. 1. Glyoxylate and dicarboxylate metabolism; 2. Pentose and glucuronate interconversions; 3. Folate biosynthesis; 4. Phenylalanine metabolism; 5. Tyrosine metabolism; 6. Citrate cycle (TCA cycle); 7. Pyrimidine metabolism; 8. Starch and sucrose metabolism; 9. Ubiquinone and other terpenoid-quinone biosynthesis; 10. Taurine and hypotaurine metabolism; 11. Ascorbate and aldarate metabolism; 12. Riboflavin metabolism; 13. Tryptophan metabolism; 14. Primary bile acid biosynthesis. (D) Serum metabolite relative pathways. 1. Arachidonic acid metabolism; 2. Glycerophospholipid metabolism; 3. Tryptophan metabolism; 4. Primary bile acid biosynthesis; 5. Steroid hormone biosynthesis; 6. Linoleic acid metabolism; 7. Biosynthesis of unsaturated fatty acids; 8. Taurine and hypotaurine metabolism; 9. α-linolenic acid metabolism; 10. Retinol metabolism; 11. Fatty acid biosynthesis; 12. Arginine and proline metabolism; 13. Fatty acid elongation in the mitochondria.
Fig.7  Reconstructed pathways associated with the biomarkers that are abnormally expressed in SQDS rats. The red script substances are the metabolic markers tentatively identified in this experiment. They are mainly involved in bile acid metabolism, retinoid acid metabolism, fatty acid metabolism, amino acid metabolism, and carbohydrate metabolism.
Fig.8  Chromatograms and multivariate analysis in serum pharmacochemistry analysis. (A) Chromatograms of the SJZD, model group serum, and SJZD-dosed group. (B) PCA score plot between the dosed and model groups. (C) Trend plot of identified absorbed compound 3.117_257.0814.
Fig.9  ES-BPI rat serum chromatogram marked with characterized compounds after orally administrated SJZD. The compounds with yellow arrows were from Ginseng, with purple arrows from poria, with blue arrows from macrocephala, and with green arrows from licorice.
Fig.10  PCMS analysis between serum biomarkers and chemical constituents in the SJZD group. The vertical arrangement is the absorption components, and the transverse arrangement is the biomarkers. Red square: means extremely positive correlation. Black square: means extremely negative correlation. Pink square: means highly positive correlation. Blue square: means highly negative correlation. Green square: means minimal correlation. The absorbed compounds marked in red were the crucial compounds, which we further screened.
Fig.11  PCMS analysis between urine biomarkers and chemical constituents in the SJZD group. The vertical arrangement is the absorption components, and the transverse arrangement is the biomarkers. Red square: means extremely positive correlation. Black square: means extremely negative correlation. Pink square: means highly positive correlation. Blue square: means highly negative correlation. Green square: means minimal correlation. The absorbed compounds marked in red were the crucial compounds, which we further screened.
Fig.12  Research route of Sijunzi decoction’s quality-marker in this experiment.
1 J Hu, B Liu. The basic theory, diagnostic, and therapeutic system of traditional Chinese medicine and the challenges they bring to statistics. Stat Med 2012; 31(7): 602–605 pmid: 22238066
2 X Liu, J Fu, T Fan, W Liu, H Jiang, R Zhang, H Ding, H Yang, S Hu, Y Huang, G Li, Y Lan, B She, B Mao. The efficacy and safety of Shen Guo Lao Nian Granule for common cold of qi-deficiency syndrome: study protocol for a randomized, double-blind, placebo-controlled, multicenter, phase II clinical trial. Evid Based Complement Alternat Med 2017; 2017(6): 1806461 pmid: 29430253
3 Q Shu, D Sun, H Wang, F Liang, L Gerhard, L Daniela, G Ingrid, L Chen, W He, Y Wang. Differences of acupuncture and moxibustion on heart rate variability in qi-deficiency syndrome:a randomized controlled trial. Chin Acup Moxib (Zhongguo Zhen Jiu) 2017; 37(1): 25–30 (in Chinese)
pmid: 29231318
4 D Xu, Z Shen, W Wang. Immunoregulation of Youguiyin, Sijunzitang, Taohong Siwutang in treating patients with deficiency of kidney, spleen and blood stasis syndrome. Chin J Integr Trad West Med (Zhongguo Zhong Xi Yi Jie He Za Zhi) 1999; 19(12): 712–714 (in Chinese)
pmid: 11783139
5 Q Hu, RM Calduch. On traditional Chinese medicine regulation in China: how quality and safety of use are insured. Pharmacol Res 2017; 119: 371–372 pmid: 28258009
6 G Wang, B Mao, ZY Xiong, T Fan, XD Chen, L Wang, GJ Liu, J Liu, J Guo, J Chang, TX Wu, TQ Li; CONSORT Group for Traditional Chinese Medicine. The quality of reporting of randomized controlled trials of traditional Chinese medicine: a survey of 13 randomly selected journals from mainland China. Clin Ther 2007; 29(7): 1456–1467 pmid: 17825697
7 Z Ning, C Lu, Y Zhang, S Zhao, B Liu, X Xu, Y Liu. Application of plant metabonomics in quality assessment for large-scale production of traditional Chinese medicine. Planta Med 2013; 79(11): 897–908 pmid: 23807813
8 TF Cheng, YR Jia, Z Zuo, X Dong, P Zhou, P Li, F Li. Quality assessment of traditional Chinese medicine herb couple by high-performance liquid chromatography and mass spectrometry combined with Chemometrics. J Sep Sci 2016; 39(7): 1223–1231 pmid: 26834048
9 C Wang, S Hu, X Chen, X Bai. Screening and quantification of anticancer compounds in traditional Chinese medicine by hollow fiber cell fishing and hollow fiber liquid/solid-phase microextraction. J Sep Sci 2016; 39(10): 1814–1824 pmid: 26987300
10 L Zhuo, J Peng, Y Zhao, D Li, X Xie, L Tong, Z Yu. Screening bioactive quality control markers of QiShenYiQi dripping pills based on the relationship between the ultra-high performance liquid chromatography fingerprint and vascular protective activity. J Sep Sci 2017; 40(20): 4076–4084 pmid: 28802088
11 X Wang, A Zhang, H Sun, G Yan. Precision diagnosis of Chinese medicine syndrome and evaluation of prescription efficacy based on Chinmedomics. Modernization Tradit Chin Med Materia Medica—World Sci Technol (Shi Jie Ke Xue Ji Shu— Zhong Yi Yao Xian Dai Hua) 2017; 19(1): 30–34 (in Chinese)
12 A Zhang, H Sun, G Yan, P Wang, Y Han, X J Wang. Chinmedomics: a new strategy for research of traditional Chinese medicine. China J Chin Materia Medica (Zhongguo Zhong Yao Za Zhi) 2015; 40(4): 569–576 (in Chinese)
13 H Wang, S Shi, S Wang. Can highly cited herbs in ancient traditional Chinese medicine formulas and modern publications predict therapeutic targets for diabetes mellitus? J Ethnopharmacol 2018; 213: 101–110 pmid: 29102765
14 X Wang, A Zhang, H Sun. Future perspectives of Chinese medical formulae: Chinmedomics as an effector. OMICS 2012; 16(7-8): 414–421 pmid: 22734809
15 X Wang, A Zhang, S Hui, Y Han, G Yan. Discovery and development of innovative drug from traditional medicine by integrated Chinmedomics strategies in the post-genomic era. Trends Analyt Chem 2016; 76: 86–94
16 XN Li, A Zhang, M Wang, H Sun, Z Liu, S Qiu, T Zhang, X Wang. Screening the active compounds of Phellodendri amurensis cortex for treating prostate cancer by high-throughput Chinmedomics. Sci Rep 2017; 7(1): 46234 pmid: 28383015
17 XH Zhou, AH Zhang, L Wang, YL Tan, Y Guan, Y Han, H Sun, XJ Wang. Novel Chinmedomics strategy for discovering effective constituents from ShenQiWan acting on ShenYangXu syndrome. Chin J Nat Med 2016; 14(8): 561–581
pmid: 27608946
18 X Wang, A Zhang, X Zhou, Q Liu, Y Nan, Y Guan, L Kong, Y Han, H Sun, G Yan. An integrated Chinmedomics strategy for discovery of effective constituents from traditional herbal medicine. Sci Rep 2016; 6(1): 18997 pmid: 26750403
19 F Liu, Y Liu, C Tian. Effect of Rhizoma Atractylodis extract in protecting gastric mucosa and modulating gastrointestinal immune function in a rat model of spleen deficiency. J Southern Med Univ (Nan Fang Yi Ke Da Xue Xue Bao) 2015; 35(3): 343–347, 354 (in Chinese)
pmid: 25818777
20 S Lu, Y Han, H Chu, L Kong, A Zhang, G Yan, H Sun, P Wang, X Wang. Characterizing serum metabolic alterations of Alzheimer’s disease and intervention of Shengmai-San by ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry. Food Funct 2017; 8(4): 1660–1671 pmid: 28379235
21 Q Zhao, A Zhang, W Zong, N An, H Zhang, Y Luan, H Sun, X Wang, H Cao. Exploring potential biomarkers and determining the metabolic mechanism of type 2 diabetes mellitus using liquid chromatography coupled to high-resolution mass spectrometry. RSC Adv 2017; 7(70): 44186–44198
22 AM de Passillé, G Pelletier, J Ménard, J Morisset. Relationships of weight gain and behavior to digestive organ weight and enzyme activities in piglets. J Anim Sci 1989; 67(11): 2921–2929 pmid: 2480340
23 A Tharakan, IT Norton, PJ Fryer, S Bakalis. Mass transfer and nutrient absorption in a simulated model of small intestine. J Food Sci 2010; 75(6): E339–E346 pmid: 20722918
24 R Clara, M Schumacher, D Ramachandran, S Fedele, JP Krieger, W Langhans, A Mansouri. Metabolic adaptation of the small intestine to short- and medium-term high-fat diet exposure. J Cell Physiol 2017; 232(1): 167–175 pmid: 27061934
25 C Mansi, P Borro, M Giacomini, R Biagini, MR Mele, N Pandolfo, V Savarino. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14(5): 561–569 pmid: 10792119
26 GJ Tortora, NP Anagnostakos. Principles of anatomy and physiology. J Anat 2009; 86(10): 555
27 SY Zhang, GY Peng, LG Gu, ZM Li, SJ Yin. Effect and mechanisms of Gong-tone music on the immunological function in rats with Liver (Gan)-qi depression and Spleen (Pi)-qi deficiency syndrome in rats. Chin J Integr Med 2013; 19(3): 212–216 pmid: 22241503
28 Z Itoh, S Takeuchi, I Aizawa, K Mori, T Taminato, Y Seino, H Imura, N Yanaihara. Changes in plasma motilin concentration and gastrointestinal contractile activity in conscious dogs. Am J Dig Dis 1978; 23(10): 929–935 pmid: 717352
29 Q Liu, G Cai. Content of somatostatin and cholecystokinin-8 in hypothalamus and colons in a rat model of spleen-deficiency syndrome. J Chin Integr Med (Zhong Xi Yi Jie He Xue Bao) 2007; 5(5): 555–558 (in Chinese) pmid: 17854559
30 RL Yong, Y Qu, XX Li, JB Wang, YN Xue, LD Zhang. Effect of electroacupuncture at “Zusanli”(ST 36) on the expression of Ghrelin/cAMP/PKA in the Jejunum in rats with spleen Qi deficiency syndrome. Acupunct Res (Zhen Ci Yan Jiu) 2016; 41(6): 497–501 (in Chinese)
pmid: 29071891
31 K Chan, K Leung, G Lu. Quality and safety should go hand in hand to monitor herbal products: examples from Chinese medicinal materials (CMM). Planta Med 2007; 73(9): 803
32 YQ Duan, YX Cheng, YJ Liang, WD Cheng, J Du, XY Yang, Y Wang. Intervention of qi-activating and spleen-strengthening herbs on Ca2+/CaMK II signaling pathways key factors in skeletal muscle tissue of rats with spleen-qi deficiency. J Chin Med Mater (Zhong Yao Cai) 2015; 38(3): 562–566 (in Chinese)
pmid: 26495660
33 XF Zheng, JS Tian, P Liu, J Xing, XM Qin. Analysis of the restorative effect of Bu-zhong-yi-qi-tang in the spleen-qi deficiency rat model using 1H-NMR-based metabonomics. J Ethnopharmacol 2014; 151(2): 912–920 pmid: 24333365
34 H Sun, AH Zhang, L Yang, MX Li, H Fang, J Xie, XJ Wang. High-throughput chinmedomics strategy for discovering the quality-markers and potential targets for Yinchenhao decoction. Phytomedicine 2019; 54: 328–338 pmid: 30340940
35 S Zhao, Z Liu, M Wang, D He, L Liu, Y Shu, Z Song, H Li, Y Liu, A Lu. Anti-inflammatory effects of Zhishi and Zhiqiao revealed by network pharmacology integrated with molecular mechanism and metabolomics studies. Phytomedicine 2018; 50: 61–72 pmid: 30466993
36 Z Yuan, L Zhong, Y Hua, P Ji, W Yao, Q Ma, X Zhang, Y Wen, L Yang, Y Wei. Metabolomics study on promoting blood circulation and ameliorating blood stasis: investigating the mechanism of Angelica sinensis and its processed products. Biomed Chromatogr 2019; 33(4): e4457 pmid: 30520064
37 P Wu, J Li, X Zhang, F Zeng, Y Liu, W Sun. Study of the treatment effects of compound Tufuling Granules in hyperuricemic rats using serum metabolomics. Evid Based Complement Alternat Med 2018; 2018: 3458185 pmid: 30410553
38 Y Dong, P Qiu, L Zhao, P Zhang, X Huang, C Li, K Chai, D Shou. Metabolomics study of the hepatoprotective effect of Phellinus igniarius in chronic ethanol-induced liver injury mice using UPLC-Q/TOF-MS combined with ingenuity pathway analysis. Phytomedicine2018 Oct 2. 152697. pmid: 30392748
39 N Tripathi, D Shrivastava, B Ahmad Mir, S Kumar, S Govil, M Vahedi, PS Bisen. Metabolomic and biotechnological approaches to determine therapeutic potential of Withania somnifera (L.) Dunal: a review. Phytomedicine 2018; 50: 127–136 pmid: 30466971
40 Y Xu, S Chen, T Yu, J Qiao, G Sun. High-throughput metabolomics investigates anti-osteoporosis activity of oleanolic acid via regulating metabolic networks using ultra-performance liquid chromatography coupled with mass spectrometry. Phytomedicine 2018; 51: 68–76 pmid: 30466629
41 L Duan, L Guo, L Wang, Q Yin, CM Zhang, YG Zheng, EH Liu. Application of metabolomics in toxicity evaluation of traditional Chinese medicines. Chin Med 2018; 13(1): 60 pmid: 30524499
42 X Wang, S Zhang, A Zhang, G Yan, X Wu, Y Han, H Sun. Metabolomics study of type 2 diabetes and therapeutic effects of Tianqijiangtang-capsule using ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry. Anal Methods 2013; 5(9): 2218–2226
43 Y Zhang, CD Klaassen. Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res 2010; 51(11): 3230–3242 pmid: 20671298
44 AB Roberts, CA Frolik, MD Nichols, MB Sporn. Retinoid-dependent induction of the in vivo and in vitro metabolism of retinoic acid in tissues of the vitamin A-deficient hamster. J Biol Chem 1979; 254(14): 6303–6309
pmid: 447714
45 JA Hall, JR Grainger, SP Spencer, Y Belkaid. The role of retinoic acid in tolerance and immunity. Immunity 2011; 35(1): 13–22 pmid: 21777796
46 XJ Wang. Progress and future developing of the serum pharmacochemistry of traditional Chinese medicine. China J Chin Mater Med (Zhongguo Zhong Yao Za Zhi) 2006; 31(10): 789–792, 835 (in Chinese)
pmid: 17048655
47 AH Zhang, JB Yu, H Sun, L Kong, XQ Wang, QY Zhang, XJ Wang. Identifying quality-markers from Shengmai San protects against transgenic mouse model of Alzheimer’s disease using Chinmedomics approach. Phytomedicine 2018; 45: 84–92 pmid: 29685366
48 H Sun, AH Zhang, Q Song, H Fang, XY Liu, J Su, L Yang, MD Yu, XJ Wang. Functional metabolomics discover pentose and glucuronate interconversion pathways as promising targets for Yang Huang syndrome treatment with Yinchenhao Tang. RSC Adv 2018; 8(64): 36831–36839
49 AH Zhang, H Sun, GL Yan, QQ Zhao, XJ Wang. Chinmedomics: a powerful approach integrating metabolomics with serum pharmacochemistry to evaluate the efficacy of traditional Chinese medicine. Engineering (Beijing) 2019; 5(1): 60–68
50 XJ Wang, HT Lv, AH Zhang, WJ Sun, L Liu, P Wang, ZM Wu, DX Zou, H Sun. Metabolite profiling and pathway analysis of acute hepatitis rats by UPLC-ESI MS combined with pattern recognition methods. Liver Int 2014; 34(5): 759–770 pmid: 24004042
51 AH Zhang, H Sun, HY Xu, S Qiu, XJ Wang. Cell metabolomics. OMICS 2013; 17(10): 495–501 pmid: 23988149
52 H Sun, AH Zhang, SB Liu, S Qiu, XN Li, TL Zhang, L Liu, XJ Wang. Cell metabolomics identify regulatory pathways and targets of magnoline against prostate cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1102–1103: 143–151 pmid: 30391728
53 AH Zhang, H Sun, XJ Wang. Urinary metabolic profiling of rat models revealed protective function of scoparone against alcohol induced hepatotoxicity. Sci Rep 2015; 4(1): 6768 pmid: 25341677
54 XY Liu, AH Zhang, H Fang, MX Li, Q Song, J Su, MD Yu, L Yang, XJ Wang. Serum metabolomics strategy for understanding the therapeutic effects of Yin-Chen-Hao-Tang against Yanghuang syndrome. RSC Adv 2018; 8(14): 7403–7413
55 AH Zhang, H Sun, GL Yan, Y Yuan, Y Han, XJ Wang. Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods. J Physiol Biochem 2014; 70(1): 117–128 pmid: 23975652
56 Q Song, AH Zhang, GL Yan, L Liu, XJ Wang. Technological advances in current metabolomics and its application in tradition Chinese medicine. RSC Adv 2017; 7(84): 53516–53524
57 AH Zhang, H Sun, WJ Sun, XJ Wang. Metabolomics and Proteomics Annotate Therapeutic Mechanisms of Geniposide[M]//Chinmedomics. Amsterdam: Academic Press, 2015: 157–173
58 QQ Zhao, AH Zhang, WJ Zong, N An, HM Zhang, YH Luan, HX Cao, H Sun, XJ Wang. Chemometrics strategy coupled with high resolution mass spectrometry for analyzing and interpreting comprehensive metabolomic characterization of hyperlipemia. RSC Adv 2016; 6(113): 112534–112543
59 XJ Wang, Y Han, AH Zhang, H Sun. Metabolic profiling provides a system for the understanding of Alzheimer’s disease in rats post-treatment with Kaixin San[M]//Chinmedomics. Amsterdam: Academic Press, 2015: 347–362
60 AH Zhang, HY Wang, H Sun, Y Zhang, N An, GL Yan, XC Meng, XJ Wang. Metabolomics strategy reveals therapeutical assessment of limonin on nonbacterial prostatitis. Food Funct 2015; 6(11): 3540–3549 pmid: 26302114
61 JL Ren, AH Zhang, L Kong, XJ Wang. Advances in mass spectrometry-based metabolomics for investigation of metabolites. RSC Adv 2018; 8(40): 22335–22350
62 AH Zhang, H Sun, XJ Wang. Mass spectrometry-driven drug discovery for development of herbal medicine. Mass Spectrom Rev 2018; 37(3): 307–320 pmid: 28009933
63 H Sun, M Wang, AH Zhang, B Ni, H Dong, XJ Wang. UPLC-Q-TOF-HDMS analysis of constituents in the root of two kinds of Aconitum using a metabolomics approach. Phytochem Anal 2013; 24(3): 263–276 pmid: 23225552
64 FF Wu, H Sun, WF Wei, Y Han, P Wang, TW Dong, GL Yan, XJ Wang. Rapid and global detection and characterization of the constituents in ShengMai San by ultra-performance liquid chromatography-high-definition mass spectrometry. J Sep Sci 2011; 34(22): 3194–3199 pmid: 22012918
65 XJ Wang, AH Zhang, H Sun, Y Han, GL Yan. Discovery and development of innovative drug from traditional medicine by integrated Chinmedomics strategies in the post-genomic era. TrAC Trends in Analytical Chemistry 2016; 76: 86–94
66 AH Zhang, H Sun, S Qiu, XJ Wang. Advancing drug discovery and development from active constituents of Yinchenhao Tang, a famous traditional Chinese medicine formula. Evid Based Complement Alternat Med 2013; 2013: 257909 pmid: 24191164
67 XJ Wang, QQ Wang, AH Zhang, FM Zhang, H Zhang, H Sun, HX Cao, HM Zhang. Metabolomics study of intervention effects of Wen-Xin-Formula using ultra high-performance liquid chromatography/mass spectrometry coupled with pattern recognition approach. J Pharm Biomed Anal 2013; 74: 22–30 pmid: 23245229
68 W Dong, P Wang, XC Meng, H Sun, AH Zhang, WM Wang, H Dong, XJ Wang. Ultra-performance liquid chromatography-high-definition mass spectrometry analysis of constituents in the root of Radix Stemonae and those absorbed in blood after oral administration of the extract of the crude drug. Phytochem Anal 2012; 23(6): 657–667 pmid: 22745030
[1] FMD-19014-OF-WXJ_suppl_1 Download
[2] FMD-19014-OF-WXJ_suppl_2 Download
[1] Hudan Pan, Yanfang Zheng, Zhongqiu Liu, Zhongwen Yuan, Rutong Ren, Hua Zhou, Ying Xie, Liang Liu. Deciphering the pharmacological mechanism of Guan-Jie-Kang in treating rat adjuvant-induced arthritis using omics analysis[J]. Front. Med., 2019, 13(5): 564-574.
[2] Li Ma, Bin Wang, Yuanxiong Long, Hanmin Li. Effect of traditional Chinese medicine combined with Western therapy on primary hepatic carcinoma: a systematic review with meta-analysis[J]. Front. Med., 2017, 11(2): 191-202.
[3] Yunfang Liu,Zhiping Yang,Jing Cheng,Daiming Fan. Barriers and countermeasures in developing traditional Chinese medicine in Europe[J]. Front. Med., 2016, 10(3): 360-376.
[4] Yan Ma,Kehua Zhou,Jing Fan,Shuchen Sun. Traditional Chinese medicine: potential approaches from modern dynamical complexity theories[J]. Front. Med., 2016, 10(1): 28-32.
[5] Guanli Song,Yinghui Wang,Runshun Zhang,Baoyan Liu,Xuezhong Zhou,Xiaji Zhou,Hong Zhang,Yufeng Guo,Yanxing Xue,Lili Xu. Experience inheritance from famous specialists based on real-world clinical research paradigm of traditional Chinese medicine[J]. Front. Med., 2014, 8(3): 300-309.
[6] Yan Ma,Shuchen Sun,Chung-Kang Peng. Applications of dynamical complexity theory in traditional Chinese medicine[J]. Front. Med., 2014, 8(3): 279-284.
[7] Yixin Zhong,Baoyan Liu,Hua Qu,Qi Xie. Methodological challenges to human medical study[J]. Front. Med., 2014, 8(3): 328-336.
[8] Li Ma,Baoyan Liu,Qi Xie,Shusong Mao,Zhiwei Cui. Ontological reconstruction of the clinical terminology of traditional Chinese medicine[J]. Front. Med., 2014, 8(3): 358-361.
[9] Junhua Zhang,Boli Zhang. Clinical research of traditional Chinese medicine in big data era[J]. Front. Med., 2014, 8(3): 321-327.
[10] Jian Wang,Biyan Liang,Xiaoping Zhang,Liran Xu,Xin Deng,Xiuhui Li,Lu Fang,Xinghua Tan,Yuxiang Mao,Guoliang Zhang,Yuguang Wang. An 84-month observational study of the changes in CD4 T-lymphocyte cell count of 110 HIV/AIDS patients treated with traditional Chinese medicine[J]. Front. Med., 2014, 8(3): 362-367.
[11] Runshun Zhang,Yinghui Wang,Baoyan Liu,Guangli Song,Xuezhong Zhou,Shizhen Fan,Xishui Pan. Clinical data quality problems and countermeasure for real world study[J]. Front. Med., 2014, 8(3): 352-357.
[12] Xuezhong Zhou,Yubing Li,Yonghong Peng,Jingqing Hu,Runshun Zhang,Liyun He,Yinghui Wang,Lijie Jiang,Shiyan Yan,Peng Li,Qi Xie,Baoyan Liu. Clinical phenotype network: the underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine[J]. Front. Med., 2014, 8(3): 337-346.
[13] Ping Liu, Songlin Liu, Gang Chen, Ping Wang. Understanding channel tropism in traditional Chinese medicine in the context of systems biology[J]. Front Med, 2013, 7(3): 277-279.
[14] Bingxue Shang, Zhifei Cao, Quansheng Zhou. Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives[J]. Front Med, 2012, 6(1): 67-78.
[15] Miao Jiang, Cheng Xiao, Gao Chen, Cheng Lu, Qinglin Zha, Xiaoping Yan, Weiping Kong, Shijie Xu, Dahong Ju, Pu Xu, Youwen Zou, Aiping Lu. Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis[J]. Front Med, 2011, 5(2): 219-228.
Full text